Compare SEAT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | HUMA |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 165.7M |
| IPO Year | 2021 | 2020 |
| Metric | SEAT | HUMA |
|---|---|---|
| Price | $5.08 | $0.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $18.06 | $6.19 |
| AVG Volume (30 Days) | 46.7K | ★ 10.1M |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | $4.60 | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.06 | $0.53 |
| 52 Week High | $18.73 | $2.55 |
| Indicator | SEAT | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 30.16 | 43.08 |
| Support Level | N/A | $0.54 |
| Resistance Level | $7.69 | $0.75 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 0.00 | 12.91 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.